Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity.
Allers
C
C
Department of Surgery, J.W. Goethe-University, Frankfurt am Main, Germany.
Eichhorn
J
J
Leckel
K
K
Brinkmann
L
L
Schmitz-Rixen
T
T
Hanisch
E
E
Markus
B H
BH
D000714:Anastomosis, Surgical / Q000379:methods; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D019819:Budesonide / Q000627:therapeutic use*; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006801:Humans; D007082:Ileum / Q000601:surgery / Q000637:transplantation; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007421:Intestine, Small / Q000637:transplantation*; D007583:Jejunum / Q000601:surgery / Q000637:transplantation; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D020123:Sirolimus / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors; D014184:Transplantation, Homologous / Q000473:pathology / Q000502:physiology*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D019819:Budesonide; D000077561:Daclizumab; D020123:Sirolimus; D016559:Tacrolimus